XERS vs. NUVB

Last updated Apr 2, 2026

Compare and contrast key facts about Xeris Biopharma Holdings, Inc. (XERS) and Nuvation Bio Inc. (NUVB).

Performance

XERS vs. NUVB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xeris Biopharma Holdings, Inc. (XERS) and Nuvation Bio Inc. (NUVB). The values are adjusted to include any dividend payments, if applicable.

XERS vs. NUVB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
XERS Xeris Biopharma Holdings, Inc.	-23.06%	131.56%	44.26%	76.69%	-54.61%	-40.45%	31.55%
NUVB Nuvation Bio Inc.	-49.67%	236.84%	76.16%	-21.35%	-77.41%	-27.35%	17.00%

Fundamentals

Market Cap XERS : $1.09B NUVB : $1.55B
EPS XERS : $0.00 NUVB : -$0.60
PS Ratio XERS : 3.54 NUVB : 24.56
PB Ratio XERS : 79.45 NUVB : 5.08
Total Revenue (TTM) XERS : $291.85M NUVB : $62.90M
Gross Profit (TTM) XERS : $171.71M NUVB : $54.46M
EBITDA (TTM) XERS : $37.67M NUVB : -$199.90M

Returns By Period

In the year-to-date period, XERS achieves a -23.06% return, which is significantly higher than NUVB's -49.67% return.

XERS

• 1D: 4.14%
• 1M: 0.33%
• YTD: -23.06%
• 6M: -24.59%
• 1Y: 18.90%
• 3Y*: 54.74%
• 5Y*: 6.02%
• 10Y*: —

NUVB

• 1D: 5.13%
• 1M: -22.77%
• YTD: -49.67%
• 6M: 21.89%
• 1Y: 157.71%
• 3Y*: 39.54%
• 5Y*: -15.06%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

XERS vs. NUVB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XERS

XERS Risk / Return Rank: 49
XERS Sharpe Ratio Rank: 52
XERS Sortino Ratio Rank: 52
XERS Omega Ratio Rank: 51
XERS Calmar Ratio Rank: 46
XERS Martin Ratio Rank: 46

NUVB

NUVB Risk / Return Rank: 84
NUVB Sharpe Ratio Rank: 86
NUVB Sortino Ratio Rank: 85
NUVB Omega Ratio Rank: 85
NUVB Calmar Ratio Rank: 83
NUVB Martin Ratio Rank: 81

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XERS vs. NUVB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and Nuvation Bio Inc. (NUVB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XERS	NUVB	Difference
Sharpe ratio Return per unit of total volatility	0.31	1.67	-1.36
Sortino ratio Return per unit of downside risk	0.89	2.46	-1.57
Omega ratio Gain probability vs. loss probability	1.12	1.34	-0.22
Calmar ratio Return relative to maximum drawdown	0.22	2.72	-2.50
Martin ratio Return relative to average drawdown	0.47	6.64	-6.17
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XERS vs. NUVB - Sharpe Ratio Comparison

The current XERS Sharpe Ratio is 0.31, which is lower than the NUVB Sharpe Ratio of 1.67. The chart below compares the historical Sharpe Ratios of XERS and NUVB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	XERS	NUVB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.31	1.67	-1.36
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.09	-0.20	+0.29
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	-0.18	0.00

Correlation

The correlation between XERS and NUVB is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

XERS vs. NUVB - Dividend Comparison

Neither XERS nor NUVB has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

XERS vs. NUVB - Drawdown Comparison

The maximum XERS drawdown since its inception was -96.22%, roughly equal to the maximum NUVB drawdown of -93.39%. Use the drawdown chart below to compare losses from any high point for XERS and NUVB.

Drawdown Indicators

	XERS	NUVB	Difference
Max Drawdown Largest peak-to-trough decline	-96.22%	-93.39%	-2.83%
Max Drawdown (1Y) Largest decline over 1 year	-46.57%	-57.55%	+10.98%
Max Drawdown (5Y) Largest decline over 5 years	-78.59%	-93.35%	+14.76%
Current Drawdown Current decline from peak	-77.82%	-69.05%	-8.77%
Average Drawdown Average peak-to-trough decline	-79.09%	-65.43%	-13.66%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.19%	23.53%	-2.34%

Volatility

XERS vs. NUVB - Volatility Comparison

The current volatility for Xeris Biopharma Holdings, Inc. (XERS) is 15.22%, while Nuvation Bio Inc. (NUVB) has a volatility of 16.34%. This indicates that XERS experiences smaller price fluctuations and is considered to be less risky than NUVB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XERS	NUVB	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.22%	16.34%	-1.12%
Volatility (6M) Calculated over the trailing 6-month period	43.33%	69.18%	-25.85%
Volatility (1Y) Calculated over the trailing 1-year period	61.79%	95.04%	-33.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	69.47%	76.00%	-6.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.84%	73.56%	+6.28%

Financials

XERS vs. NUVB - Profitability Comparison

The chart below illustrates the profitability comparison between Xeris Biopharma Holdings, Inc. and Nuvation Bio Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

XERS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Xeris Biopharma Holdings, Inc. reported a gross profit of 0.00 and revenue of 85.81M. Therefore, the gross margin over that period was 0.0%.

NUVB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported a gross profit of 41.44M and revenue of 41.87M. Therefore, the gross margin over that period was 99.0%.

XERS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Xeris Biopharma Holdings, Inc. reported an operating income of 16.77M and revenue of 85.81M, resulting in an operating margin of 19.6%.

NUVB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported an operating income of -34.04M and revenue of 41.87M, resulting in an operating margin of -81.3%.

XERS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Xeris Biopharma Holdings, Inc. reported a net income of 11.08M and revenue of 85.81M, resulting in a net margin of 12.9%.

NUVB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported a net income of -36.59M and revenue of 41.87M, resulting in a net margin of -87.4%.